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OBJECTIVES We studied the outcome of diabetics enrolled in the Global Use of Strategies to Open
Occluded Coronary Arteries (GUSTO) V trial to assess whether the combination of
half-dose reteplase and abciximab provides any propitious benefits over standard fibrinolytic
therapy in diabetic patients.
BACKGROUND Diabetics with acute ST-segment elevation myocardial infarction (MI) have a worse outcome
compared with nondiabetics. Higher-risk patients are usually more likely to benefit from
advances in medical therapy.
METHODS We analyzed diabetic patients enrolled in the GUSTO V trial to assess the outcome of those
randomized to the combination of half-dose reteplase and abciximab versus those randomized
to reteplase. We also evaluated whether any differences existed in presentation and outcome
of MI among the diabetics versus the nondiabetics enrolled in the study.
RESULTS The trial enrolled 13,782 nondiabetics and 2,633 diabetics. Compared to nondiabetics,
diabetics had a significantly higher mortality at 30 days (8.5% vs. 5.1%, p  0.001) and at 1
year (12.7% vs. 7.5%, p 0.001). Among the diabetic subset, no significant difference existed
in the incidence of 30-day (8.8% vs. 8.2%, p  0.52) or 1-year mortality (13.0% vs. 12.4%,
p  0.62) among patients randomized to reteplase compared to those receiving combination
of abciximab and reteplase. The incidence of reinfarction (2.5% vs. 4.3%, p  0.013),
recurrent ischemia (11.8% vs. 14.9%, p  0.017), and urgent revascularization (10.9% vs.
13.3%, p  0.055) at seven days was lower in diabetics treated with the combination therapy.
CONCLUSIONS Compared to nondiabetics, diabetics continue to have a worse outcome with MI. Although
combination therapy did not provide a survival benefit, nonfatal ischemic outcomes, including
reinfarction, recurrent ischemia, and urgent revascularization, were substantially
reduced. (J Am Coll Cardiol 2004;43:542–8) © 2004 by the American College of
Cardiology Foundationi
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riabetes is a major health problem, with over 7% of the
.S. population afflicted with the disease (1). Cardiovascu-
ar disease is the leading cause of mortality and morbidity in
he diabetic population (2). Diabetes not only imparts a
reater risk of myocardial infarction (MI) but is also
ssociated with a worse short- and long-term outcome after
n MI (3,4).
Several encouraging pilot studies suggested earlier and
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ingdom. The GUSTO V trial was sponsored by Centocor (Malvern, Pennsylvania)
nd Eli Lilly (Indianapolis, Indiana).
Manuscript received May 6, 2003; revised manuscript received July 29, 2003,jccepted September 8, 2003.mproved myocardial reperfusion in patients presenting
ith MI treated with combined half-dose plasminogen
ctivator and platelet glycoprotein (GP) IIb/IIIa antag-
nists (5,6). Diabetics have evidence of increased platelet
eactivity (7–9) and appear to derive an enhanced benefit
rom GP IIb/IIIa platelet receptor antagonists (10 –12).
he Global Use of Strategies to Open Occluded Coro-
ary Arteries (GUSTO) V was a large-scale randomized
rial designed to detect a mortality difference between
tandard fibrinolytic therapy and the combination of
educed-dose fibrinolytic and abciximab in patients pre-
enting with acute ST-segment elevation MI (13). Com-
ination therapy did not significantly reduce mortality in
hat trial, although rates of reinfarction and urgent
evascularization were significantly diminished. The ob-
ective of our study was to determine if diabetic patients
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February 18, 2004:542–8 Diabetes and Combination Therapyave a different pattern of benefit from combination
herapy compared with nondiabetics. Furthermore, we
ompared the diabetic population enrolled in GUSTO V
ith those enrolled in the previous GUSTO I and
USTO III trials to study the appropriate use of adjunc-
ive therapies and outcome of diabetics over the last
ecade.
ETHODS
he design and results of GUSTO V have been previously
eported (13). In the GUSTO V trial, 16,588 patients with
T-segment elevation MI were randomly assigned between
uly 1999 and February 2001 to receive reteplase (two 10-U
oluses 30 min apart) or the combination of abciximab
infusion of 0.25 mg/kg bolus and 0.125 g/kg/min, [max-
mum of 10 g/min] infusion for 12 h) plus half-dose
eteplase (two boluses of 5 U, 30 min apart). All patients
ere given aspirin. The participating investigator deter-
ined the use of all other adjunctive medications.
The primary end point of the GUSTO V study was
ll-cause mortality at 30 days. Reinfarction was defined by
rolonged chest pain associated with new significant elec-
rocardiographic (ECG) changes, an increase in cardiac
nzyme concentration, or both. Recurrent ischemia was
efined as symptoms lasting5 min, ECG changes, and/or
ew hypotension, pulmonary edema or murmur, believed by
he physician to represent myocardial ischemia without
CG, or enzymatic evidence of infarction. These and all
ther complications of acute MI were prospectively defined
nd recorded for all patients until day 7 or hospital discharge
whichever was earlier). Percutaneous revascularization was
ecorded as urgent if defined so by the investigator. Bleeding
as classified as severe when associated with hemodynamic
ompromise, moderate when requiring transfusion without
emodynamic compromise, and mild without transfusion or
emodynamic compromise. Diabetes was defined on the
asis of patient report.
The design and outcome of GUSTO I and GUSTO III
rials have been previously described (14,15). The GUSTO
trial randomized 41,021 patients between December 1990
nd February 1993 to four different thrombolytic strategies:
treptokinase and subcutaneous heparin; streptokinase and
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
ECG  electrocardiogram/electrocardiographic
GP  glycoprotein
GUSTO  Global Use of Strategies to Open Occluded
Coronary Arteries trial
IV  intravenous
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary interventionntravenous (IV) heparin; accelerated tissue plasminogen Ictivator (t-PA) and IV heparin; or a combination of
treptokinase plus t-PA with IV heparin (14). All patients
eceived aspirin and beta-blockers (if not contraindicated),
hereas use of other adjunctive medications was at the
iscretion of the treating physician. The GUSTO III trial
andomized 15,059 patients between October 1995 and
anuary 1997 with acute ST-elevation MI to accelerated
-PA or reteplase (15). All patients received aspirin and IV
eparin. Use of all other adjunctive medications was deter-
ined by the treating physician. To compare outcome and
resentation across GUSTO I, GUSTO III, and GUSTO
trials, we included patients from the 11 countries that
ere common to the three trials (Australia, Belgium,
anada, France, Germany, United Kingdom, Netherlands,
oland, Spain, Switzerland, and the U.S.).
tatistical analysis. Baseline characteristics were summa-
ized by the use of frequencies and percentages for categor-
cal factors and means and standard deviation for continuous
actors. Differences in baseline characteristics were tested
ith Pearson chi-square tests for categorical factors and
ilcoxon rank-sum tests for continuous variables. Multi-
ariable logistic models were used to estimate the adjusted
dds of 30-day death for the diabetic population. Spline
ransformations were used for pulse rate and blood pressure
nd logarithmic transformation for time from symptom
nset to study drug. The interactions between various
ariables were explored, and the significant interaction
erms incorporated in the model. A value of p  0.05 was
sed as the level for statistical significance. The SAS version
.12 (SAS Inc., Cary, North Carolina) was used as the
tatistical software.
ESULTS
USTO V. The GUSTO V trial enrolled 13,782 nondia-
etics and 2,633 diabetics. The baseline characteristics of
he diabetics and nondiabetics are shown in Table 1.
iabetics tended to be older and included a greater percent-
ge of women and minorities as compared with nondiabet-
cs. They were more likely to have hypertension, hypercho-
esterolemia, peripheral vascular disease, and prior history of
I and coronary revascularization. They were less likely to
ave a family history of premature coronary artery disease or
o be current smokers. Further, diabetics were more likely to
resent late after onset of symptoms, to have anterior MI,
nd to have a higher heart rate and a worse Killip class at
resentation. The 30-day mortality was significantly higher
n diabetics (Table 2), and there was a trend toward a greater
ncidence of reinfarction. Diabetics had a significantly
igher mortality at one year compared to nondiabetics
12.7% vs. 7.5%, p  0.001).
Table 3 describes the characteristics of the diabetic
atients randomized to reteplase versus combination ther-
py. The groups were evenly matched, with a slightly greater
ean age in the group randomized to combination therapy.n concordance with the overall cohort of the trial, there was
n
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Diabetes and Combination Therapy February 18, 2004:542–8o difference in the 30-day or one-year mortality among
iabetics randomized to the two arms of GUSTO V (Fig.
). A significant decrease occurred in the number of patients
eveloping reinfarction or recurrent ischemia (Table 4) and
trend toward a decrease in the need for urgent revascu-
arization with the combination of abciximab and half-dose
eteplase. Use of combination therapy was associated with a
ignificant reduction in the composite of death, MI, recur-
ent angina, or ischemia and revascularization at seven days
odds ratio [OR] 0.83, 95% confidence interval [CI] 0.71 to
.97, p 0.021) and the composite of MI, recurrent angina
r ischemia and revascularization at seven days (OR 0.81,
5% CI 0.69 to 0.95, p  0.008). Furthermore, patients
andomized to the combination therapy were overall less
ikely to develop complications of MI (Table 4). Although
o difference was seen in the incidence of mechanical
omplications or heart failure, ventricular tachyarrhythmias
ere less likely in patients receiving the combination therapy.
nd even though combination therapy was associated with
xcess risk of bleeding, no increases in intracranial bleeding rate
r blood transfusion occurred with this regimen.
Table 1. Baseline Characteristics of Patients E
Age (mean yrs)
Age 75 yrs
Female
Current smoker
Body mass index (mean)
Caucasian
Treated hypertension
Treated hypercholesterolemia
Family history of early CAD
History of PVD
Previous history of MI
Prior PCI
Prior CABG
Anterior MI
Mean systolic blood pressure at presentation
(mm Hg)
Mean heart rate at presentation
Killip class
1
2
3
4
CABG  coronary artery bypass grafting; CAD  coronary
coronary intervention; PVD  peripheral vascular disease.
Table 2. Outcome of Patients Enrolled in GU
N
(n
Death at 30 days 5
Reinfarction within 7 days 2
Urgent CAGB or PCI within 7 days 12
Death, MI, or urgent revascularization
within 7 days
16
Death at 1 year 7Abbreviations as in Table 1.Table 5 depicts the major predictors of 30-day mortality
n diabetics. The model had a c statistic of 0.83, suggesting
ood discrimination. Four easily identifiable variables (age,
eart rate, systolic blood pressure, and Killip class) provide
lmost 85% of the prognostic information with respect to
azard of 30-day mortality.
Compared with nondiabetics, the diabetics enrolled in
USTO V were more likely to receive angiotensin-
onverting enzyme (ACE) inhibitors (67.3% vs. 56.5%, p
.001), calcium channel blockers (11.6% vs. 9.1%, p 
.001), digoxin (7.9% vs. 5.1%, p 0.001), inotropic agents
9.9% vs. 7.6%, p  0.001), and nitrates (75.3% vs. 71.6%,
 0.001). They were less likely to receive aspirin (93.2%
s. 94.9%, p  0.002); little difference was noted in the use
f beta-blockers (83.5% vs. 84.9%, p  0.116).
iabetics in GUSTO I, GUSTO III, and GUSTO V. To
ompare outcome and adjunctive medication use among
iabetics over the last decade, we compared 5,376 dia-
etics in GUSTO I, 1,886 in GUSTO III, and 1,938 in
USTO V enrolled in the 11 common countries. There
as a trend toward an improvement in survival across the
ed in GUSTO V Based on Diabetes
ndiabetic
 13,782)
Diabetic
(n  2,633) p Value
1  12 64  11 0.001
% (1,797) 16% (422) 0.001
% (3,193) 32.2% (848) 0.001
% (6,631) 32.1% (835) 0.001
9  4.03 28.38  4.72 0.001
% (13,774) 93.6% (2,632) 0.001
% (4,172) 51.9% (1,357) 0.001
% (2,049) 26.1% (658) 0.001
% (3,815) 27.1% (601) 0.001
% (582) 8.3% (195) 0.001
% (1,943) 20.9% (540) 0.001
% (846) 9.3% (241) 0.001
% (415) 4.9% (127) 0.001
% (5,085) 40.0% (1,052) 0.001
4  23 138  24 0.01
4  17 79  19 0.001
0.001
% (12,308) 83.8% (2,204)
% (1,269) 13.2% (347)
% (122) 2.3% (60)
% (63) 0.7% (18)
disease; MI  myocardial infarction; PCI  percutaneous
V Based on Diabetic Status
abetic
3,782)
Diabetic
(n  2,633) p Value
709) 8.5% (223) 0.001
385) 3.4% (90) 0.08
1,665) 12.1% (318) 0.996
2,315) 19.0% (499) 0.007
1027) 12.7% (334) 0.001nroll
No
(n
6
13
23.2
48.5
26.7
96.6
30.4
15.2
31.2
4.6
14.2
6.2
3.0
36.9
13
7
89.4
9.2
0.9
0.5
arterySTO
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February 18, 2004:542–8 Diabetes and Combination Therapyast decade (Table 6) although no improvement in
urvival of patients presenting in Killip class 3 and class 4
as noted. Furthermore, there was a greater utilization of
ppropriate adjunctive therapies in these patients, as seen
n the increased use of beta-blockers and ACE inhibitors.
ISCUSSION
ata from the three GUSTO trials corroborate and extend
revious evidence that, compared to nondiabetics, diabetics
ave worse outcome after MI. The large number of diabet-
cs enrolled in GUSTO V provide a unique opportunity to
tudy the impact of this disease on the morbidity and
igure 1. Outcome of diabetics with myocardial infarction randomized to
Table 3. Baseline Characteristics of Diabetic P
Treatment Arm
(n
Age (mean yrs)
Age 75 yrs 15
Female 32
Current smoker 32
Body mass index (mean) 28
Caucasian 9
Treated hypertension 51
Treated hypercholesterolemia 26
Family history of early CAD 28
History of PVD 7
Previous history of MI 20
Prior PCI 9
Prior CABG 4
Anterior MI 40
Mean systolic blood pressure at presentation
(mm Hg)
Mean heart rate at presentation
Killip class
1 84
2 13
3 2
4 0
Abbreviations as in Table 1.I  confidence interval; PCI  percutaneous coronary intervention.ortality associated with MI. Compared to nondiabetics,
iabetics continue to present with a higher Killip class and
ave a worse outcome with MI. Although combination
herapy did not provide a survival benefit, it was associated
ith a reduction in the incidences of reinfarction, recurrent
schemia, and urgent revascularization.
Diabetes is a rapidly growing health problem, with
pproximately 4% of adults being diabetics worldwide (16).
he epidemic appears to be accelerating, with a projected
00 million diabetics by the year 2025 (16). Cardiovascular
isease is a major cause of mortality and morbidity in
iabetics, and multiple studies have suggested a markedly
rd versus combination therapy. CABG  coronary artery bypass grafting;
ts Enrolled in GUSTO V Based on
lase
,299)
Reteplase  Abciximab
(n  1,334) p Value
11 65  11 0.04
205) 16.3% (217) 0.73
422) 31.9% (416) 0.76
419) 31.6% (416) 0.57
4.74 28.38  4.70 0.90
1,207) 94.2% (1,257) 0.16
658) 52.6% (699) 0.46
328) 25.8% (330) 0.72
312) 26.0% (289) 0.24
84) 9.4% (111) 0.06
260) 21.4% (280) 0.51
118) 9.3% (123) 0.91
55) 5.4% (72) 0.16
526) 39.4% (526) 0.56
24 138  23 0.72
19 79  19 0.60
0.058
1,091) 83.5% (1,113)
172) 13.1% (175)
27) 2.5% (33)
6) 0.9% (12)standaatien
Retep
 1
64 
.8% (
.5% (
.6% (
.38 
3% (
.1% (
.4% (
.3% (
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.3% (
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Diabetes and Combination Therapy February 18, 2004:542–8orse outcome in diabetics presenting with ST-segment
levation or non–ST-segment elevation MI (3,4).
Recent evidence points to emergence of platelets as key
ediators in acute coronary syndromes (17). Diabetics have
vidence of increased platelet activation (7), adhesiveness
nd aggregability (8), and greater expression of platelet GP
Ib/IIIa, thrombospondin, and P selectin (9). Based on
hese lines of evidence, potent platelet inhibition may be of
articular benefit in diabetic patients presenting with acute
oronary syndromes. While all subjects appeared to benefit
rom peri-procedural abciximab, the diabetic substudy of
valuation of platelet IIb/IIIa inhibitor for stenting trial
EPISTENT) suggested an enhanced outcome in diabetics
andomized to abciximab (11). Combined analysis from
hree major percutaneous coronary intervention (PCI) trials
uggested a marked one-year mortality benefit of abciximab
n diabetics undergoing PCI (12). Similar enhanced benefits
f tirofiban in diabetics have been reported in the setting of
cute coronary syndromes (18). Roffi et al. (10) performed a
Table 4. Complications of MI and its Treatme
Combination Therapy
(
Any complication of index MI
Reinfarction
Recurrent ischemia/angina
Composite of 7-day death, MI, recurrent
ischemia/angina or revascularization
4
Composite of 7-day MI, recurrent ischemia/
angina or revascularization
4
New severe CHF
Myocardial rupture
Ventricular septal defect
Sustained ventricular tachycardia
Ventricular fibrillation
Atrial fibrillation
Asystole
2nd or 3rd degree heart block
Intracranial hemorrhage
Any bleeding
Blood transfusion
CHF  congestive heart failure; MI  myocardial infarctio
Table 5. Predictors of 30-Day Mortality in Di
Odds Ratio
Age (yrs) 1.073
SBP (115 mm Hg)* 0.969
SBP (115 mm Hg)* 0.972
Pulse (58/min)† 1.000
Pulse (58/min)† 1.023
Killip class III and IV 4.638
Anterior infarct 1.584
History of PVD 1.772
Current smoker 0.552
Weight 90 kg 0.538
*Systolic blood pressure (SBP) had a varying effect on mor
proportional reduction in the hazard of mortality below an
hazard above an SBP of 115 mm Hg. †A rising pulse was as
of 58. No relationship was seen between mortality and a heCI  confidence interval; PVD  peripheral vascular disease.eta-analysis of all major trials of platelet GP IIb/IIIa
nhibitors in non–ST-segment elevation acute coronary
yndrome and described a reduction in 30-day mortality in
iabetics from 4.0% to 1.2% (p  0.002). This improved
utcome in diabetics in PCI and acute coronary syndromes
aises the question of possible enhanced benefit for diabetics
n the setting of ST-segment elevation MI as well.
The randomized design and the large number of diabetic
atients enrolled in GUSTO V provided an almost matched
opulation in the two arms. In parallel with the main trial,
o significant mortality difference was noted between pa-
ients treated with reteplase or combination therapy. How-
ver, the consistent reductions in reinfarction, recurrent
schemia, urgent revascularization, and malignant ventricu-
ar arrhythmias as seen in the main trial suggest additional
enefits of enhanced platelet suppression achieved using
ombination therapy. Fibrinolytic agents lyse fibrin-
hrombin clot and release free thrombin, which is a potent
timulator of platelet aggregation (19).
Diabetics Randomized to Standard Versus
lase
,299)
Reteplase  Abciximab
(n  1,334) p Value
(465) 30.0% (400) 0.002
(56) 2.5% (34) 0.013
(194) 11.8% (157) 0.017
(584) 40.54% (540) 0.021
(529) 35.74% (476) 0.008
(86) 7.0 (93) 0.721
(8) 0.7% (9) 0.851
(4) 0.2% (3) 0.722
(42) 1.9% (26) 0.038
(47) 2.1% (28) 0.019
(66) 4.5% (60) 0.483
(35) 3.2% (43) 0.423
(45) 2.5% (34) 0.169
(13) 0.6% (8) 0.004
(184) 26.7% (356) 0.001
(71) 6.5% (86) 0.288
cs in a Multivariable Model
95% CI Chi-Square p Value
1.052–1.094 49.764 0.001
0.950–0.989 9.165 0.003
0.962–0.983 26.986 0.001
0.939–1.064 0 1.000
1.014–1.032 26.343 0.001
2.537–8.479 24.848 0.001
1.123–2.234 6.863 0.009
1.088–2.887 5.287 0.022
0.334–0.887 6.029 0.014
0.327–0.884 5.984 0.014
hazard. Each 1 mm Hg rise was associated with a greater
f 115 mm Hg compared to a somewhat lesser reduction in
ed with an increasing hazard of mortality above a heart rate
lower than 58.nt in
Retep
n  1
35.8%
4.3%
14.9%
4.99%
0.76%
6.6
0.6%
0.3%
3.2%
3.6%
5.1%
2.7%
3.5%
1.0%
14.2%
5.5%abeti
tality
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February 18, 2004:542–8 Diabetes and Combination TherapyCombination therapy would hence be expected to specif-
cally impact on the platelet-mediated recurrent ischemic
vents and distal embolization. Indeed, the current data
upport the previously described reduction in clinical events
nd improved tissue level perfusion with combination ther-
py (5,20). These improvements in key complications of MI
re at the cost of an increase in mild and moderate bleeding.
owever, the need for transfusions or the incidence of
ntracranial hemorrhage was not higher in the combination
rm, hence suggesting an acceptable safety profile.
These findings are in contrast to those from the Assess-
ent of the Safety and Efficacy of a New Thrombolytic
egimen (ASSENT)-III study (21), which suggested a
orse outcome among diabetic patients receiving half-dose
enecteplase and abciximab combination therapy compared
o those receiving tenecteplase and heparin. These results
rom ASSENT-III are probably a reflection of the small
umber of diabetics in that study (355 in the combination
herapy arm versus 363 in the unfractionated heparin plus
enecteplase arm and 380 in the enoxaparin plus tenect-
plase arm) and may exemplify a type I statistical error.
lternatively, these differences may relate to the different
gents used or differences in the patients enrolled and are
est delineated in an adequately powered prospective study.
Previous experience with abciximab in the setting of
rimary PCI for ST-segment elevation MI has been even
ore encouraging. The small number (53) of diabetics
nrolled in the Abciximab before Direct Angioplasty and
tenting in Myocardial Infarction Regarding Acute and
ong-Term Follow-up (ADMIRAL) trial who received
bciximab in the setting of stenting for ST-segment eleva-
ion MI had a significant reduction in the six-month
ortality rate as compared with those randomized to
lacebo (0% vs. 16.7%, p 0.02) (22). Further, a significant
eduction occurred in the composite of death, reinfarction,
r any revascularization. Reminiscent of the data in acute
oronary syndrome, the benefit of abciximab appeared to be
nhanced in diabetics compared to nondiabetics. The lack
f similar findings in GUSTO V may suggest vital differ-
nce in the role of abciximab in the setting of two differing
trategies of reperfusion. Whereas more evidence supports
he efficacy of such therapy in primary PCI, the lack of
Table 6. Outcome and Medication Use in Diab
Diabetic Subset
GUS
(1990
Diabetics/total 5,376/
(14
Death (30 days) 10
30 day-mortality (Killip class I and II) 9
30-day mortality (Killip class III and IV) 44
Beta-blocker use 75
ACE inhibitor use 28
Aspirin use 98
ACE  angiotensin-converting enzyme.ortality benefit with combination therapy makes its rou- oine use less compelling and suggests a need for further
esearch to clarify its role in clinical practice.
Compared with the GUSTO I and GUSTO III trials,
USTO V was marked by an improvement in 30-day
urvival after MI. This improvement was seen in both
iabetics and nondiabetics and may represent temporal
rends in improved therapy or differences in type of enrolled
atients. A comparison of diabetics and nondiabetics sug-
ests a worse outcome in diabetics in concordance with
revious work. The key predictive variables of outcome in
iabetics were similar to those in the nondiabetic popula-
ion. Heart rate and blood pressure retained a major
redictive role in this population despite the theoretical
oncerns of dysautonomia.
Concern has been raised that diabetics are less likely to
eceive appropriate adjunct therapy following an MI. Using
he Monitoring Trends and Determinants in Cardiovascular
isease (MONICA) Augsburg registry, Lowel and col-
eagues (23) found marked underutilization of beta-blockers
uring hospitalization and at discharge in diabetics.
cGuire et al. (3) also described a lower use of beta-
lockers (68.4% vs. 72.4%, p  0.001) in diabetics com-
ared with nondiabetics in the GUSTO-IIb study. Con-
erns about masking of hypoglycemia in diabetics may have
een responsible in part for the underutilization of such
roven therapy. In GUSTO V, diabetics and nondiabetics
ere equally likely to receive beta-blockers, whereas diabet-
cs were actually more likely to receive angiotensin-
onverting enzyme (ACE) inhibitors, calcium channel
lockers, and digoxin. This may reflect the increased aware-
ess of benefits of ACE inhibitors in diabetics and the
ncreased prevalence of hypertension and congestive heart
ailure in this group. A comparison across GUSTO I,
USTO III, and GUSTO V shows an appropriate increase
n use of beta-blockers and ACE inhibitors in diabetics.
he use of aspirin decreased somewhat and could not be
ccounted for by increased bleeding complications, random-
zation arm, or use of adenosine diphosphate antagonists,
he latter being used in only a small minority of aspirin
onusers (data not shown). This increased utilization of the
ppropriate and proven therapies may directly contribute to
n GUSTO I, GUSTO III, and GUSTO V
)
GUSTO III
(1995–1997)
GUSTO V
(1999–2001) p Value
0 1,886/11,996
(15.7%)
1,938/12,603
(15.4%)
10.9% 8.9% 0.06
9.6% 7.5% 0.04
44.1% 50.0% 0.722
75.7% 83.5% 0.001
54.9% 67.3% 0.001
98.6% 93.2% 0.001etics i
TO I
–1993
37,11
.5%)
.7%
.3%
.5%
.1%
.9%
.1%r may be a marker of better overall care, which in turn
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utcome of diabetics in GUSTO V.
tudy limitations. Our analysis was a retrospective sub-
roup analysis, and hence it is subject to the known
imitations regarding sample size and spurious findings
nherent in such work. Diabetes was defined by patient
eport and may have led to significant underreporting of
iabetes. No data on HbA1c or blood glucose at presenta-
ion were available. Further, time to ST-segment resolution
as available only in a small number of diabetics, thus
recluding study of effect of combination therapy on micro-
ascular perfusion. The diabetic substudy was underpowered
o detect a mortality difference at 30 days, although our
ndings parallel those of the main trial and thus are likely to
e extant. These findings should be considered hypothesis
enerating and hence require validation in prospective
tudies.
Differing enrollment criteria, varying practice patterns,
nd evidence base and different therapeutic agents being
ested limit the comparison of diabetics across the three
USTO trials. We have accordingly limited our analysis to
rovide general information about use of adjunctive thera-
ies as a barometer of practice patterns across similar centers
ver the last decade.
onclusions. Diabetes continues to be associated with a
orse outcome after ST-segment elevation MI, in part
wing to the more serious associated co-morbidities and
artly due to a worse clinical presentation. There has been
n improvement in outcome and use of appropriate adjunct
herapy in diabetics when compared to historical controls.
s in nondiabetics, combination therapy appears to reduce
he risk of recurrent ischemia, reinfarction, need for revas-
ularization, and ventricular tachyarrhythmias in diabetics
ithout any improvement in either short- or long-term
ortality. Although the improvement in secondary end
oints with combination therapy provides a small step
orward, the continued high short- and long-term mortality
einforces the significance of the burden associated with a
ommon and growing public health problem.
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